Celularity Inc. Increase (Decrease) in Accounts Receivable
Celularity Inc. (CELU) reported Increase (Decrease) in Accounts Receivable of -$7.55 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-04-30.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsReceivable · last filed 2026-04-30
- Celularity Inc. increase (decrease) in accounts receivable for the quarter ending 2025-12-31 was -$548.00K, a 110.91% decline year-over-year.
- Celularity Inc. increase (decrease) in accounts receivable for the quarter ending 2025-09-30 was -$4.54M.
- Celularity Inc. increase (decrease) in accounts receivable for the quarter ending 2025-06-30 was -$3.81M.
- Celularity Inc. increase (decrease) in accounts receivable for the quarter ending 2025-03-31 was $1.35M, a 65.60% decline year-over-year.
- Celularity Inc. increase (decrease) in accounts receivable for fiscal 2025 was -$7.55M, a 290.30% decline from fiscal 2024.
- Celularity Inc. increase (decrease) in accounts receivable for fiscal 2024 was $3.97M, a 41.88% decline from fiscal 2023.
- Celularity Inc. increase (decrease) in accounts receivable for fiscal 2023 was $6.83M, a 90.49% increase from fiscal 2022.
- Celularity Inc. increase (decrease) in accounts receivable for fiscal 2022 was $3.58M, a 87.74% increase from fiscal 2021.
| Period end | Increase (Decrease) in Accounts Receivable 3 month | Increase (Decrease) in Accounts Receivable 6 month | Increase (Decrease) in Accounts Receivable 9 month | Increase (Decrease) in Accounts Receivable 12 month |
|---|---|---|---|---|
| 2025-12-31 | -$548.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-30 | -$5.09M derived: sum of 2 quarters · filed 2026-04-30 | -$8.90M derived: sum of 3 quarters · filed 2026-04-30 | -$7.55M 10-K · filed 2026-04-30 |
| 2025-09-30 | -$4.54M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | -$8.35M derived: sum of 2 quarters · filed 2025-11-14 | -$7.00M 10-Q · filed 2025-11-14 | -$1.98M derived: sum of 4 quarters · filed 2026-04-30 |
| 2025-06-30 | -$3.81M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-29 | -$2.46M 10-Q · filed 2025-08-29 | $2.56M derived: sum of 3 quarters · filed 2026-04-30 | -$2.22M derived: sum of 4 quarters · filed 2026-04-30 |
| 2025-03-31 | $1.35M 10-Q · filed 2025-08-29 | $6.37M derived: sum of 2 quarters · filed 2026-04-30 | $1.59M derived: sum of 3 quarters · filed 2026-04-30 | $1.39M derived: sum of 4 quarters · filed 2026-04-30 |
| 2024-12-31 | $5.02M derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-30 | $236.00K derived: sum of 2 quarters · filed 2026-04-30 | $44.00K derived: sum of 3 quarters · filed 2026-04-30 | $3.97M 10-K · filed 2026-04-30 |
| 2024-09-30 | -$4.79M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | -$4.98M derived: sum of 2 quarters · filed 2025-11-14 | -$1.05M 10-Q · filed 2025-11-14 | $5.66M derived: sum of 4 quarters · filed 2025-11-14 |
| 2024-06-30 | -$192.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-29 | $3.73M 10-Q · filed 2025-08-29 | $10.44M derived: sum of 3 quarters · filed 2025-08-29 | $11.82M derived: sum of 4 quarters · filed 2025-08-29 |
| 2024-03-31 | $3.92M 10-Q · filed 2025-08-29 | $10.63M derived: sum of 2 quarters · filed 2025-08-29 | $12.02M derived: sum of 3 quarters · filed 2025-08-29 | $11.54M derived: sum of 4 quarters · filed 2025-08-29 |
| 2023-12-31 | $6.71M derived: 10-K 12 month − 10-Q 9 month · filed 2025-05-08 | $8.09M derived: sum of 2 quarters · filed 2025-05-08 | $7.62M derived: sum of 3 quarters · filed 2025-05-08 | $6.83M 10-K · filed 2025-05-08 |
| 2023-09-30 | $1.38M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-12-06 | $909.00K derived: sum of 2 quarters · filed 2024-12-06 | $118.00K 10-Q · filed 2024-12-06 | $1.01M derived: sum of 4 quarters · filed 2024-12-06 |
| 2023-06-30 | -$475.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-11-07 | -$1.27M 10-Q · filed 2024-11-07 | -$370.00K derived: sum of 3 quarters · filed 2024-11-07 | $1.13M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-03-31 | -$791.00K 10-Q · filed 2024-10-16 | $105.00K derived: sum of 2 quarters · filed 2024-10-16 | $1.60M derived: sum of 3 quarters · filed 2024-10-16 | $1.68M derived: sum of 4 quarters · filed 2024-10-16 |
| 2022-12-31 | $896.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-07-30 | $2.39M derived: sum of 2 quarters · filed 2024-07-30 | $2.47M derived: sum of 3 quarters · filed 2024-07-30 | $3.58M 10-K · filed 2024-07-30 |
| 2022-09-30 | $1.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-01-03 | $1.58M derived: sum of 2 quarters · filed 2024-01-03 | $2.69M 10-Q · filed 2024-01-03 | $3.84M derived: sum of 4 quarters · filed 2024-01-03 |
| 2022-06-30 | $79.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $1.19M 10-Q · filed 2023-08-14 | $2.35M derived: sum of 3 quarters · filed 2023-08-14 | $3.19M derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-03-31 | $1.11M 10-Q · filed 2023-05-22 | $2.27M derived: sum of 2 quarters · filed 2023-05-22 | $3.11M derived: sum of 3 quarters · filed 2023-05-22 | $3.21M derived: sum of 4 quarters · filed 2023-05-22 |
| 2021-12-31 | $1.16M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | $2.00M derived: sum of 2 quarters · filed 2023-03-31 | $2.09M derived: sum of 3 quarters · filed 2023-03-31 | $1.91M 10-K · filed 2023-03-31 |
| 2021-09-30 | $844.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $939.00K derived: sum of 2 quarters · filed 2022-11-10 | $754.00K 10-Q · filed 2022-11-10 | $567.00K derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $95.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | -$90.00K 10-Q · filed 2022-08-09 | -$277.00K derived: sum of 3 quarters · filed 2022-08-09 | |
| 2021-03-31 | -$185.00K 10-Q · filed 2022-05-16 | -$372.00K derived: sum of 2 quarters · filed 2022-05-16 | ||
| 2020-12-31 | -$187.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | -$1.65M 10-K · filed 2022-03-31 | ||
| 2020-09-30 | -$1.47M 10-Q · filed 2021-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 |